Menarini Silicon Biosystems has reported new secondary analysis results from the PACE trial, reinforcing the potential of its CELLSEARCH Circulating Tumor Cell (CTC) enumeration system as a predictive biomarker for guiding treatment escalation in hormone receptor-positive, HER2-negative metastatic breast cancer. Published in Clinical Cancer Research, the findings suggest that CTC counts in blood samples could help oncologists decide whether patients progressing after aromatase inhibitors and CDK4/6 inhibitors would benefit more from intensified combination therapy or remain on endocrine monotherapy.

Why the PACE biomarker analysis marks a shift in therapeutic decision-making

The PACE biomarker analysis addresses a growing gap in managing second-line metastatic breast cancer. With limited consensus on post-progression therapy after CDK4/6 inhibition, oncologists currently rely on an evolving mix of clinical experience, genomic data, and trial evidence. The PACE trial introduces a new decision tool: CTC burden, objectively measured, stratifies patients into risk tiers with implications for how aggressively to treat them.

In the PACE trial, patients with fewer than 5 CTCs per 7.5 mL of blood were categorized as having indolent disease, while those with 5 or more were considered to have aggressive disease. Among patients in the aggressive disease category, those treated with combination therapy experienced significant improvements in progression-free survival. Specifically, doublet therapy reduced the risk of progression by 57%, and triplet therapy by 74%, compared to endocrine monotherapy.

However, this benefit was not observed in patients with indolent disease. Their outcomes did not meaningfully improve with intensified regimens, which may suggest overtreatment risks if combination therapy is administered indiscriminately.

Why CTC enumeration stands out from ctDNA and traditional risk metrics

One of the central claims emerging from the PACE data is that CTC enumeration can act independently from traditional clinical risk factors and circulating tumor DNA profiles. This has significant implications. While ctDNA analysis has become a cornerstone of genomic monitoring, it may not always reflect phenotypic aggressiveness or real-time cellular viability. CTC testing, in contrast, offers morphological and kinetic insight into tumor dynamics that complements existing molecular tools.

The field has long sought a reliable and objective stratification marker for treatment de-escalation. Industry observers tracking the liquid biopsy space note that CTC-based assessments could fill this role, especially in cases where genomic drivers are ambiguous or resistance patterns remain elusive after first-line failure.

This independence of CTC count was also validated in the STIC trial, published in 2024, where treatment decisions based on CTC enumeration diverged from physician judgment in a significant number of cases. Importantly, in discordant scenarios, the CTC-guided approach frequently yielded superior clinical outcomes or enabled safe de-escalation.

What this could mean for clinical adoption in second-line therapy

Incorporating CTC burden into treatment decisions introduces the possibility of more nuanced care pathways for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. For those with aggressive disease, early intervention with multi-agent therapy could extend progression-free intervals, while others may avoid unnecessary toxicity and cost by staying on monotherapy.

This approach challenges the default sequencing logic that has dominated breast oncology for years. Rather than assuming all post-CDK4/6 progressors require next-line intensification, clinicians could apply an evidence-based filter using CTC enumeration to decide case-by-case.

However, barriers to clinical implementation remain. Despite its CE marking and CLIA accreditation, CELLSEARCH is not yet approved by the United States Food and Drug Administration for treatment guidance in this context. The PACE trial data may influence future regulatory applications, but for now, its use remains investigational. That distinction carries consequences for payer coverage, physician confidence, and integration into clinical workflows.

Why scalability and standardization remain key questions

Despite growing validation, CTC enumeration still faces hurdles in scaling as a routine clinical tool. Unlike ctDNA tests, which are now widely offered across decentralized labs and commercial providers, CTC-based platforms often require specialized infrastructure and centralized processing. This can delay results and reduce accessibility in lower-resource or community oncology settings.

Reimbursement is another unknown. Without a regulatory-approved indication for treatment selection, payers may view the test as discretionary. As more prospective data accumulates and as the cost of managing progressive disease escalates, the economic argument for testing will likely gain traction. But for now, the path to guideline inclusion and widespread uptake remains uncertain.

Furthermore, CTC enumeration does not fully solve the problem of biological complexity. Clinicians and diagnostic developers alike acknowledge that CTC count offers a simplified risk metric. It does not differentiate between resistance mechanisms, nor does it capture dynamic tumor evolution beyond what is sampled in peripheral blood.

What stakeholders should monitor as CTC-driven stratification enters the clinical spotlight

Several milestones could shape the future trajectory of CELLSEARCH and competing circulating tumor cell (CTC) technologies in the next wave of metastatic breast cancer treatment innovation. Regulatory watchers will be closely monitoring any movement toward formal label expansion in the United States, particularly as more post-marketing and investigational-use trial data emerges. The U.S. Food and Drug Administration may face increasing pressure to evaluate CTC-based stratification not just as a monitoring tool but as a predictive biomarker with therapeutic implications.

Clinical guideline bodies such as the American Society of Clinical Oncology and the European Society for Medical Oncology could also play a critical role in validating the clinical relevance of CTC enumeration. Their endorsement would significantly accelerate adoption across academic centers and community practices alike. Inclusion in treatment algorithms would not only legitimize use of CELLSEARCH and similar CTC enumeration platforms, but also open the door to reimbursement eligibility under value-based care models.

At the same time, the liquid biopsy field continues to evolve rapidly. Multi-analyte platforms that combine CTCs, circulating tumor DNA (ctDNA), and RNA transcripts—integrated with artificial intelligence-driven interpretation engines—are expanding the frontier of precision oncology. These systems aim to provide dynamic, longitudinal views of tumor evolution, resistance mechanisms, and actionable biomarker changes, potentially surpassing the single-modality footprint of CELLSEARCH. Startups and diagnostics firms entering this competitive space are increasingly leveraging machine learning to identify composite risk signatures, which may pose both clinical and economic challenges for Menarini Silicon Biosystems.

Despite being the first clinically validated and CE-marked CTC test with broad adoption in Europe and China, CELLSEARCH must continue demonstrating differentiated value. This includes not only the clinical accuracy of its enumeration system, but also its ability to scale across diverse patient populations, integrate with electronic health records, and offer rapid turnaround in real-world settings. Automation, interoperability, and cost-efficiency will become deciding factors as hospital systems and diagnostic labs weigh adoption across oncology service lines.

Ultimately, the value proposition of CTC-guided therapy decisions will depend on how effectively they improve progression-free survival, reduce overtreatment, and enable personalized escalation or de-escalation strategies in metastatic hormone receptor-positive, HER2-negative breast cancer. Menarini Silicon Biosystems is positioning itself at the intersection of biomarker-guided precision oncology and real-time treatment optimization. Whether this approach achieves mainstream clinical acceptance will depend not just on evidence, but on the ecosystem’s readiness to reframe how breast cancer progression is evaluated and acted upon.

  CDK4/6 inhibitors, CELLSEARCH, circulating tumor cells, liquid biopsy, Menarini Silicon Biosystems, metastatic breast cancer, PACE trial